Taking all the previous results together, we found that high expression of YTHDF2 and TRMT6 is closely correlated with advanced WHO stage, IDH mutation, 1p19q non-codel, and poor clinical outcome in glioma. This evidence concerns the gene TRMT6 and central nervous system cancer.